Enterprise Value

176.9M

Cash

293.8M

Avg Qtr Burn

-45.91M

Short % of Float

44.68%

Insider Ownership

34.42%

Institutional Own.

68.15%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Imvotamab (IGM-2323) (CD20 x CD3) Details
Systemic lupus erythematosus, Autoimmune disease

Phase 1b

Update

Imvotamab (IGM-2323) (CD20 x CD3) Details
Autoimmune disease, Rheumatoid arthritis

Phase 1b

Initiation

Imvotamab (IGM-2323) (CD20 x CD3) Details
Idiopathic inflammatory myopathy / myositis

Phase 1

Data readout

Phase 1

Data readout

IGM-7354 (IL-15 x PD-L1) Details
Solid tumor/s, Cancer, Hematologic malignancies

Phase 1

Update

Phase 1

Update

Aplitabart (IGM-8444) + birinapant Details
Hematologic malignancies, Solid tumor/s

Phase 1

Update

Phase 1

Update

Imvotamab (IGM-2323) (CD20 x CD3) Details
Cancer, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma

Failed

Discontinued

IGM-6268 Details
Solid tumor/s, Cancer

Failed

Discontinued